Le Lézard
Classified in: Health, Science and technology
Subjects: PDT, TRI

Trialize Announces Launch of TDOM: Bridging Interoperability in Clinical Trials


ZUG, Switzerland, April 22, 2024 /PRNewswire/ -- Trialize (https://trialize.io) is proud to unveil the Trial Data Object Model (TDOM), an innovative open-source framework designed to enhance interoperability among various e-clinical systems. Tailored for clinical trials, TDOM aims to standardize data exchange, boosting efficiency, accuracy, and the speed of data sharing.

The fragmented nature of clinical data management systems has traditionally led to inefficient data exchanges and elevated costs. With the increasing complexity of global clinical trials, a standardized data exchange framework is crucial. TDOM meets this need by facilitating seamless integration and real-time data sharing, enabling quicker, more informed decision-making in clinical research.

TDOM's primary goal is to establish a universally accepted framework for data interoperability in clinical trials.

Objectives include:

TDOM will directly benefit clinical researchers, data managers, and IT professionals by simplifying data management and ensuring integrity across systems. Pharmaceutical companies and regulatory bodies will indirectly benefit from faster development of medical treatments due to more efficient research processes.

Given the global nature of clinical trials, TDOM is designed to be relevant and adaptable worldwide, ensuring consistency in clinical data management across different regulatory environments. This approach aims to set a new standard in clinical data management, enhancing efficiency in multinational research collaborations.

Stakeholders and Collaboration:
Key stakeholders include clinical researchers, healthcare professionals, pharmaceutical companies, and regulatory bodies. Successful implementation of TDOM relies on collaborative efforts among these groups to ensure the framework meets global clinical research needs.

Invitation to Collaborate:
Trialize invites stakeholders across clinical research and data management to participate in this groundbreaking initiative. Collaboration in the development and implementation of TDOM offers a chance to shape the future of clinical trials, keeping the industry at the forefront of technological and healthcare innovation.

Contact:
For more information on TDOM or to join the collaboration, please contact TDOM Working Group at [email protected]

About Trialize:
Trialize (https://trialize.io) is a leader in clinical trial software solutions, dedicated to improving the efficiency and effectiveness of clinical research. Our technologies are designed to streamline clinical trial processes, ensuring faster and more reliable outcomes.

The launch of TDOM marks a significant advancement in clinical research technology, enhancing data interoperability and accelerating the pace of medical research globally.

Media Contact:
Anna Sunden
+1 863 216 8448
[email protected]

SOURCE Trialize


These press releases may also interest you

at 13:35
Phoenix-Micron, Inc. ("Phoenix"), recognized globally for its leadership in in vivo ophthalmic imaging of small animals, today announced the MICRON Animal Stand - Pro. For the first time, inhalation anesthetic delivery is integrated into an animal...

at 13:15
Neurocrine Biosciences, Inc. , today presented the CAHtalysttm Pediatric Phase 3 clinical study baseline characteristics data for...

at 13:15
Julie Bank, chief people officer at Brighton Health Plan Solutions, has received an OnCon Icon Award for 2024. This award reflects voting by her peers that ranks her among the top 50 human resources professionals working worldwide....

at 12:46
Melmark, a nationally-recognized non-profit human services provider recently held its biennial fundraising gala, The Dream Maker's Ball: Melmark Generations. Over 200 guests gathered at the Crystal Tea Room in Philadelphia on Saturday, April 20th to...

at 12:25
The "Hematology Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering. Hematology Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the hematology...

at 12:20
Johnson & Johnson announced today results from the open-label, single-arm Phase 2 Apa-RP study evaluating adjuvant treatment with ERLEADA® (apalutamide) and androgen deprivation therapy (ADT) in patients with HRLPC who have undergone...



News published on and distributed by: